Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ronrydellon Jun 26, 2013 4:57pm

31 Views

Post# 21574692

RE:Would be nice to have the news release at end of trading on friday and then give us all a chance to digest over the long weekend. Have the conference call for tuesday morning!

Great numbers the last two days...no problem waiting 'till mid July for a release..the market is telling us that we'll hear something soon and that it could be good. A stable $3 share price is great considering we all have some Zenith shares besides.

if we hear earlier that's great also.

Bullboard Posts

How one company is disrupting PoC testing